The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART

Journal of Medical Virology

Volumn 81, Issue 8, 2009, Pages 1323-1335

  Castor, Delivette ^a   Vlahov, David ^a,b   Hoover, Donald R ^c   Berkman, Alan ^a   Ying, Feng Wu ^b   Zeller, Barbara ^d   Brechtl, John ^e   Hammer, Scott M ^a  

^a Department of Medicine   (United States)

^b NEW YORK ACADEMY OF MEDICINE   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d HELP/Project Samaritan AIDS Services   (United States)

^e Terence Cardinal Cooke Health Care Center   (United States)

Author keywords

Adherence; DAART; HAART; HIV resistance; HIV AIDS

Indexed keywords

RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HEALTH CARE FACILITY; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE ADHERENCE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT INFORMATION; PRACTICE GUIDELINE; PREDICTIVE VALIDITY; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; REMISSION; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS RESISTANCE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 68049100224     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21500     Document Type: Article

References (44)

1. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA. 2001. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 345:398-407. (Pubitemid 32747603)
2. Anderson JA, Jiang H, Ding X, Petch L, Journigan T, Fiscus SA, Haubrich R, Katzenstein D, Swanstrom R, Gulick RM. 2008. Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses 24:685-694. (Pubitemid 351748774)
3. Badri SM, Adeyemi OM, Max BE, Hota BN, Barker DE. 2007.Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure. AIDS Patient Care STDS 21:544-550.
4. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A, PillayD,Porter K, Pozniak A, SabinC, SmitE,Weber J, Zuckerman M. 2005. Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. Br Med J 331:1368. (Pubitemid 43773487)
5. CDC. 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41:1-19.
6. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R, De Luca A. 2002. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 16:369-379. (Pubitemid 34165368)
7. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM. 2002. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16:579-588. (Pubitemid 34218853)
8. Cole SR, Hernan MA, Margolick JB, Cohen MH, Robins JM. 2005. Marginal structuralmodels for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. AmJ Epidemiol 162:471-478. (Pubitemid 41191433)
9. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero J, Rhodes A , Robbins HL, Roth E, ShivaprakashM, Titus D, Yang T, Tepplert H, Squires KE, Deutsch PJ, Emini EA. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
10. Crane HM, Van Rompaey SE, Dillingham PW, Herman E, Diehr P, Kitahata MM. 2006. A single-item measure of health-related quality-of-life for HIV-infected patients in routine clinical care. AIDS Patient Care STDS 20:161-174.
11. De Luca A, Cingolani A, Di Giambenedetto S, Trotta MP, Baldini F, Rizzo MG, Bertoli A, Liuzzi G, Narciso P, Murri R, Ammassari A, Perno CF, Antinori A. 2003. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 187:1934-1943. (Pubitemid 36724492)
12. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, ParaM, Yerly S, Zolopa A,Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 5:41-48. (Pubitemid 30261205)
13. Delaugerre C, Morand-Joubert L, Chaix ML, Picard O, Marcelin AG, Schneider V, Krivine A, Compagnucci A, Katlama C, Girard PM, Calvez V. 2004. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 9:415-421. (Pubitemid 38878757)
14. DHHS. 2006. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, Department of Health and Human Services.
15. DHHS. 2008. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. pp. 1-128.
16. Graham N, Peeters M, Verbiest W, Harrigan R, Larder B. 2001. The virtual phenotype is an independent predictor of clinical response. 8th Conference on Retroviruses and Opportunitstic Infections 2001, Chicago, Illinois, Abstract # 524.
17. Greenberg B, Berkman A, Thomas R, Hoos D, Finkelstein R, Astemborski J, Vlahov D. 1999. Evaluating supervised HAART in late-stage HIV among drug users: A preliminary report. J Urban Health 76:468-480.
18. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW. 2002. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. J Am Med Assoc 288:169-180. (Pubitemid 34755277)
19. Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, Wood R, Larder BA. 2001. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: Biologically relevant values for resistance testing. AIDS 15:1671-1677. (Pubitemid 32918121)
20. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA. 2002. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: A prospective cohort analysis. AIDS 16:F33-F40. (Pubitemid 35205260)
21. Haupts S, Ledergerber B, Boni J, Schupbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Gunthard HF. 2003. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antivir Ther 8: 443-454. (Pubitemid 37351563)
22. Hertogs K, Bloor S,KempSD,Van denEynde C, Alcorn TM, PauwelsR, Van Houtte M, Staszewski S,Miller V, Larder BA. 2000. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples. AIDS 14:1203-1210.
23. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD. 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 37:113-128. (Pubitemid 36836653)
24. Hirsch HH, Drechsler H, Holbro A, Hamy F, Sendi P, Petrovic K, Klimkait T, Battegay M. 2005.Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care. Eur J Clin Microbiol Infect Dis 24:733-738. (Pubitemid 41752069)
25. Jiang H, Deeks SG, Kuritzkes DR, Lallemant M, Katzenstein D, Albrecht M, DeGruttola V. 2003. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis 188:1001-1008. (Pubitemid 37268250)
26. Johnson V, Brun-Vezinet F, Clotet B, Conway B, D' Aquila DT, Demeter LM, Kurtzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD, International AIDS Society-USA Drug Resistance Mutations Group. 2003. Drug resistance mutations in HIV-1. Topics HIV Med 11:215-221.
27. King MS, Rode R, Cohen-Codar I, Calvez V, Marcelin AG, Hanna GJ, Kempf DJ. 2007. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob Agents Chemother 51:3067-3074. (Pubitemid 350067510)
28. Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, Perneger TV, Perrin L, Kaiser L, Yerly S. 1999. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 13:F17-F21. (Pubitemid 29050401)
29. Loutfy MR, Raboud JM, Walmsley SL, Saskin R, Montaner JS, Hogg RS, Thompson CA, Harrigan PR. 2004. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Antivir Ther 9:595-602. (Pubitemid 39150217)
30. Lucas GM, Gallant JE, Moore RD. 2004. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS 18:1539-1548.
31. Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G,Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G. 2003. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (Gen-PheRex) trial. J Acquir Immune Defic Syndr 32:268-280. (Pubitemid 36331698)
32. Palmer S, Shafer RW, Merigan TC. 1999. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 13:661-667. (Pubitemid 29286700)
33. Pepe MS, Anderson GL. 1994. A cautionary note on inference for marginal regression models with longitudinal data and general correlated response data. Commun Stat Simulat Comput 23:939-951.
34. Perez-Elias MJ, Garcia-Arota I, Munoz V, Santos I, Sanz J, Abraira V, Arribas JR, Gonzalez J, MorenoA,Dronda F, Antela A, Pumares M, Marti-Belda P, Casado JL, Geijos P, Moreno S. 2003. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: A prospective, randomized study. Antivir Ther 8:577-584. (Pubitemid 38057103)
35. Perez-Elias MJ, Moreno A, Moreno S, Lopez D, Antela A, Casado JL, Dronda F, Gutierrez C, Quereda C, Navas E, Abraira V, Rodriguez MA. 2005. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. HIV Clin Trials 6:312-319. (Pubitemid 43336965)
36. Roge BT, Katzenstein TL, Nielsen HL, Gerstoft J. 2003. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavircontaining HAART. HIV Med 4:38-47. (Pubitemid 37161535)
37. Schapiro JM, Winters MA, Lawrence J, Merigan TC. 1999. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS 13:359-365. (Pubitemid 29095098)
38. Shafer RW, Winters MA, Palmer S, Merigan TC. 1998. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 128:906-911. (Pubitemid 28289485)
39. Torti C, Quiros-Roldan E, Keulen W, Scudeller L, Lo Caputo S,Boucher C, Castelli F, Mazzotta F, Pierotti P, Been-Tiktak AM, Buccoliero G, De Gennaro M, Carosi G, Tinelli C. 2003. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: Concordance analysis and correlation with clinical outcome in heavily treated patients. J Infect Dis 188:194-201. (Pubitemid 36898150)
40. van Maarseveen NM, Huigen MC, de Jong D, Smits AM, Boucher CA, NijhuisM. 2006. A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants. J Virol Methods 133:185-194.
41. Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vezinet F, Peytavin G, Costagliola D, Girard PM. 2003. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther 8:427-434. (Pubitemid 37351561)
42. Zeger SL, Liang KY. 1986. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121-130.
43. Zhang J, Rhee SY, Taylor J, Shafer RW. 2005. Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays. J Acquir Immune Defic Syndr 38:439-444. (Pubitemid 40381554)
44. Ziermann R, Celis L, Derdelinckx I, Lambert C, Veeck J, Rizzo MG, Vanderborght B, Zissis G, Clumeck N, Fransen K, Vaira D, Hendricks D, Van Laethem K, Vandamme AM, Schmit JC, Knechten H, De Luca A, Louwagie J, Segers P, De Boeck K, Pottel H, De Brauwer A, Hulstaert F. 2004. Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system. J Clin Virol 31:S7-S15. (Pubitemid 39574704)